As systemic cancer therapies improve and are able to control metastatic disease outside the central nervous system, the brain is increasingly the first site of relapse. The blood–brain barrier (BBB) represents a major challenge to the delivery of therapeutics to the brain. Macrophages originating from circulating monocytes are able to infiltrate brain metastases while the BBB is intact. Here, we show that this ability can be exploited to deliver both diagnostic and therapeutic nanoparticles specifically to experimental brain metastases of breast cancer
Brain metastasis, an important cause of cancer morbidity and mortality, occurs in at least 30% of pa...
More and more people in the world suffer from various brain diseases such as Parkinson’s disease, Al...
Brain tumors are responsible for almost 2% of deaths in the Western world. The most used methods now...
HER2‐targeted therapies effectively control systemic disease, but their efficacy against brain metas...
Brain metastases present an increasing challenge to long-term survival for HER2-amplified breast ca...
Metastatic brain cancers, in particular cancers with multiple lesions, are one of the most difficult...
Brain metastasis is a major cause of death in patients with solid cancers. Breast cancer cells have ...
The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and posses...
Nanotechnology-based drug delivery was born as a chance for pharmaceutical weapons to be delivered i...
""Nanotechnology-based drug delivery was born as a chance for pharmaceutical weapons to be delivered...
Nanotechnology-based drug delivery was born as a chance for pharmaceutical weapons to be delivered i...
The treatment for central nervous system metastases of solid tumors and gliomas is limited as the bl...
Delivering therapeutics to the central nervous system (CNS) and brain-tumor has been a major challen...
Brain metastases of human epidermal growth factor receptor 2 (HER2)-positive breast cancer are prese...
The blood–brain barrier (BBB) is partially disrupted in brain tumors. Despite the gaps in the BBB, t...
Brain metastasis, an important cause of cancer morbidity and mortality, occurs in at least 30% of pa...
More and more people in the world suffer from various brain diseases such as Parkinson’s disease, Al...
Brain tumors are responsible for almost 2% of deaths in the Western world. The most used methods now...
HER2‐targeted therapies effectively control systemic disease, but their efficacy against brain metas...
Brain metastases present an increasing challenge to long-term survival for HER2-amplified breast ca...
Metastatic brain cancers, in particular cancers with multiple lesions, are one of the most difficult...
Brain metastasis is a major cause of death in patients with solid cancers. Breast cancer cells have ...
The blood–brain barrier (BBB) is a barrier that separates the blood from the brain tissue and posses...
Nanotechnology-based drug delivery was born as a chance for pharmaceutical weapons to be delivered i...
""Nanotechnology-based drug delivery was born as a chance for pharmaceutical weapons to be delivered...
Nanotechnology-based drug delivery was born as a chance for pharmaceutical weapons to be delivered i...
The treatment for central nervous system metastases of solid tumors and gliomas is limited as the bl...
Delivering therapeutics to the central nervous system (CNS) and brain-tumor has been a major challen...
Brain metastases of human epidermal growth factor receptor 2 (HER2)-positive breast cancer are prese...
The blood–brain barrier (BBB) is partially disrupted in brain tumors. Despite the gaps in the BBB, t...
Brain metastasis, an important cause of cancer morbidity and mortality, occurs in at least 30% of pa...
More and more people in the world suffer from various brain diseases such as Parkinson’s disease, Al...
Brain tumors are responsible for almost 2% of deaths in the Western world. The most used methods now...